One Case of Acute Pulmonary Embolism Induced by Combination of Mirtazapine and Clomipramine Tablets

Abstract

CLC Number:

R994.11

LIU Yan-hui, YANG Su-qiao, WANG Ying, CUI Xiang-li. One Case of Acute Pulmonary Embolism Induced by Combination of Mirtazapine and Clomipramine Tablets[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 375-376.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I6/375

References

[1] Chan C M, Woods C, Shorr A F.The validation and reproducibility of the pulmonary embolism severity index[J]. Journal of Thrombosis& Haemostasis Jth, 2010, 8(7):1509-1514.
[2] 徐庆, 徐薇. 14例急性肺栓塞原因分析[J]. 心脑血管病防治, 2010, 10(5):393-394.
[3] 郑晓圆, 刘瑞, 吕娟,等. 炔雌醇环丙孕酮片致肺栓塞1例[J]. 中国药物警戒, 2017, 14(6):381-382.
[4] Wu C S, Chang C M, Chen C Y, et al.Association between antidepressants and venous thromboembolism in Taiwan[J]. Journal of Clinical Psychopharmacology, 2013, 33(1):31-37.
[5] 杜文民, 王永铭, 程能能. 药品不良反应的判定与其研究方法(续完)[J]. 中国药物警戒, 2005, 2(1):11-13.
[6] Jick S S, Li L.Antidepressant drug use and risk of venous thromboembolism[J]. Pharmacotherapy the Journal of Human Pharmacology& Drug Therapy, 2008, 28(2):144-150.
[7] Parkin L, Skegg D C, Herbison G P, et al.Psychotropic drugs and fatal pulmonary embolism[J].Pharmacoepidemiology & Drug Safety, 2003, 12(8):647-652.
[8] Zink M, Knopf U, Argiriou S, et al.A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone[J]. Journal of Clinical Psychiatry, 2006, 67(5):835.
[9] Tam D W H. Sudden death from pulmonary hypertension in a depressed patient: A case report[J]. Hong Kong Journal of Psychiatry, 2009, 19(4):155-158.
[10] Le M J, Bailey D, Baker G B.Selective serotonin reuptake inhibitors and myocardial infarction[J]. Circulation, 2001, 104(16):1894-1898.
[11] Meijer W E E, Heerdink E R, Nolen W A, et al. Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants[J]. Archives of Internal Medicine, 2004, 164(21):2367-2370.
[12] 中华医学会心血管病学分会肺血管病学组. 急性肺栓塞诊断与治疗中国专家共识(2015)[J]. 中华心血管病杂志, 2016, 44(3):197-211.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.